Expression Patterns of ER, HER2, and NM23-H1 in Breast Cancer Patients with Different Menopausal Status

Breasted JH. The Edwin Smith surgical papyrus. Chicago (IL): University of Chicago Press, 1990: 403–6 Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC CancerBase No 5, version 2.0. Lyon: IARC Press, 2004 Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58(2): 71–96 Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55(2): 74–108 Hu YH, Chisato N, Hiroyuki S, et al. Association of body mass index, physical activity, and reproductive histories with breast cancer: a case-control study in Gifu, Japan. Breast Cancer Res Treat 1997; 43: 65–72 Tung HT, Tsukuma H, Tanaka H, et al. Risk factors for breast cancer in Japan, with special attention to anthropometric measurements and reproductive history. Jpn J Clin Oncol 1999; 29: 137–46 Hilakivi-Clarke L, Cabanes A, Olivo S, et al. Do estrogens always increase breast cancer risk? J Steroid Biochem Mol Biol 2002; 80: 163–74 Lin KH, Wang WJ, Wu YH, et al. Activation of antimetastatic Nm23-H1 gene expression by estrogen and its alpha-receptor. Endocrinology 2002; 143(2): 467–75 Read LD, Keith Jr D, Slamon DJ, et al. Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res 1990; 50(13): 3947–51 Ménard S, Fortis S, Castiglioni F, et al. HER2 as a prognostic factor in breast cancer. Oncology 2001; 61Suppl. 2: 67–72 Tovey S, Dunne B, Witton CJ, et al. Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer? Clin Cancer Res 2005; 11: 4835–42 Harari D, Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 2000; 19: 6102–14 Sugarbaker EV. Patterns of metastasis in human malignancies. Cancer Biol Rev 1981; 2: 235–78 Steeg PS, Bevilacqua G, Kopper L, et al. Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst 1988; 80(3): 200–4 Rosengard AM, Krutzsch HC, Shearn A, et al. Reduced Nm23/Awd protein in tumour metastasis and aberrant Drosophila development. Nature 1989; 342(6246): 177–80 Stahl JA, Leone A, Rosengard AM, et al. Identification of a second human nm23 gene, nm23-H2. Cancer Res 1991; 51(1): 445–9 Venturelli D, Martinez R, Melotti P, et al. Overexpression of DR-nm23, a protein encoded by a member of the nm23 gene family, inhibits granulocyte differentiation and induces apoptosis in 32Dc13 myeloid cells. Proc Natl Acad Sci U S A 1995; 92(16): 7435–9 Milon L, Rousseau-Merck MF, Munier A, et al. nm23-H4, a new member of the family of human nm23/nucleoside diphosphate kinase genes localised on chromosome 16p13. Hum Genet 1997; 99(4): 550–7 Munier A, Feral C, Milon L, et al. A new human nm23 homologue (nm23-H5) specifically expressed in testis germinal cells. FEBS Lett 1998; 434(3): 289–94 Mehus JG, Deloukas P, Lambeth DO. NME6: a new member of the nm23/nucleoside diphosphate kinase gene family located on human chromosome 3p21.3. Hum Genet 1999; 104(6): 454–9 Tsuiki H, Nitta M, Furuya A, et al. A novel human nucleoside diphosphate (NDP) kinase, Nm23-H6, localizes in mitochondria and affects cytokinesis. J Cell Biochem 1999; 76(2): 254–69 Van Golen KL, Risin S, Staroselsky A, et al. Predominance of the metastatic phenotype in hybrids formed by fusion of mouse and human melanoma clones. Clin Exp Metastasis 1996; 14(2): 95–106 Padma P, Hozumi A, Ogawa K, et al. Molecular cloning and characterization of a thioredoxin/nucleoside diphosphate kinase related dynein intermediate chain from the ascidian, Ciona intestinalis. Gene 2001; 275(1): 177–83 Freije JM, MacDonald NJ, Steeg PS. Nm23 and tumour metastasis: basic and translational advances. Biochem Soc Symp 1998; 63: 261–71 Orgéas CC, Hall P, Rosenberg LU, et al. The influence of menstrual risk factors on tumor characteristics and survival in postmenopausal breast cancer. Breast Cancer Res 2008; 10(6): R107 American Joint Committee on Cancer. AJCC cancer staging manual. 6th ed. New York: Springer-Verlag; 2003 [online]. Available from URL: http://www.cancerstaging.org/products/pasteditions.html [Accessed 2011 Jul 12] Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101(10): 736–50 Guarneri V, Giovannelli S, Ficarra G, et al. Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management. Oncologist 2008; 13(8): 838–44 Rhee J, Han SW, Oh DY, et al. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. BMC Cancer 2008; 8: 307 Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118–45 Belev B, Alerić I, Vrbanec D, et al. Nm23 gene product expression in invasive breast cancer: immunohistochemical analysis and clinicopathological correlation. Acta Oncol 2002; 41(4): 355–61 Gruber CJ, Tschugguel W, Schneeberger C, et al. Production and actions of estrogens. N Engl J Med 2002; 346(5): 340–52 Dickson RB, Huff KK, Spencer EM, et al. Induction of epidermal growth factor-related polypeptides by 17 beta-estradiol in MCF-7 human breast cancer cells. Endocrinology 1986; 118(1): 138–42 Wilding G, Lippman ME, Gelmann EP. Effects of steroid hormones and peptide growth factors on protooncogene c-fos expression in human breast cancer cells. Cancer Res 1988; 48(4): 802–5 Dickson RB, McManaway ME, Lippman ME. Estrogen-induced factors of breast cancer cells partially replace estrogen to promote tumor growth. Science 1986; 232(4757): 1540–3 Dubik D, Dembinski TC, Shiu RP. Stimulation of c-myc oncogene expression associated with estrogen-induced proliferation of human breast cancer cells. Cancer Res 1987; 47 (24 Pt 1): 6517–21 Sapino A, Pietribiasi F, Bussolati G, et al. Estrogen- and tamoxifen-induced rearrangement of cytoskeletal and adhesion structures in breast cancer MCF-7 cells. Cancer Res 1986; 46(5): 2526–31 Huff KK, Lippman ME. Hormonal control of plasminogen activator secretion in ZR-75-1 human breast cancer cells in culture. Endocrinology 1984; 114(5): 1702–10 Albini A, Graf J, Kitten GT, et al. 17-β-Estradiol regulates and v-Ha-ras transfection constitutively enhances MCF7 breast cancer cell interactions with basement membrane. Proc Natl Acad Sci U S A 1986; 83(21): 8182–6 Capony F, Morisset M, Barrett AJ, et al. Phosphorylation, glycosylation and proteolytic activity of the 52-kD estrogen induced protein secreted by MCF-7 cells. J Cell Biol 1987; 104(2): 253–62 Laudadio J, Quigley DI, Tubbs R, et al. HER2 testing: a review of detection methodologies and their clinical performance. Expert Rev Mol Diagn 2007; 7(1): 53–64 Frogne T, Laenkholm AV, Lyng MB, et al. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor positive tumors. Breast Cancer Res 2009; 11(1): R11 Berno V, Amazit L, Hinojos C, et al. Activation of estrogen receptor-alpha by E2 or EGF induces temporally distinct patterns of large-scale chromatin modification and mRNA transcription. PLoS One 2008; 3(5): e2286 Baird DT, Horton R, Longcope C, et al. Steroid dynamics under steady-state conditions. Recent Prog Horm Res 1969; 25: 611–64 Barrett-Lee PJ, Travers MT, McClelland RA, et al. Characterization of estrogen receptor messenger RNA in human breast cancer. Cancer Res 1987; 47: 6653–9 Benz CC. Impact of aging on the biology of breast cancer. Crit Rev Oncol Hematol 2008; 66(1): 65–74 de la Rosa A, Williams RL, Steeg PS. Nm23/nucleoside diphosphate kinase: toward a structural and biochemical understanding of its biological functions. Bioessays 1995; 17(1): 53–62 Nakayama T, Ohtsuru A, Nakao K, et al. Expression in human hepatocellular carcinoma of nucleoside diphosphate kinase, a homologue of the nm23 gene product. J Natl Cancer Inst 1992; 84(17): 1349–54 Yamaguchi A, Urano T, Goi T, et al. Expression of human nm23-H1 and nm23-H2 proteins in hepatocellular carcinoma. Cancer 1994; 73(9): 2280–4 Iizuka N, Oka M, Noma T, et al. NM23-H1 and NM23-H2 messenger RNA abundance in human hepatocellular carcinoma. Cancer Res 1995; 55(3): 652–7 Royds JA, Stephenson TJ, Rees RC, et al. Nm23 protein expression in ductal in situ and invasive human breast carcinoma. J Natl Cancer Inst 1993; 85(9): 727–31 Kodera Y, Isobe K, Yamauchi M, et al. Expression of nm23-H1 RNA levels in human gastric cancer tissues: a negative correlation with nodal metastasis. Cancer 1994; 73(2): 259–65 Mandai M, Konishi I, Koshiyama M, et al. Expression of metastasis-related nm23-H 1 and nm23-H2 genes in ovarian carcinomas: correlation with clinicopathology, EGFR, c-erbB-2, and c-erbB-3 genes, and sex steroid receptor expression. Cancer Res 1994; 54(7): 1825–30 Viel A, Dall’Agnese L, Canzonieri V, et al. Suppressive role of the metastasis-related nm23-H1 gene in human ovarian carcinomas: association of high messenger RNA expression with lack of lymph node metastasis. Cancer Res 1995; 55(12): 2645–50 Scambia G, Ferrandina G, Marone M, et al. nm23 in ovarian cancer: correlation with clinical outcome and other clinicopathologic and biochemical prognostic parameters. J Clin Oncol 1996; 14(2): 334–42 Ozeki Y, Takishima K, Mamiya G. Immunohistochemical analysis of nm23/NDP kinase expression in human lung adenocarcinoma: association with tumor progression in Clara cell type. Jpn J Cancer Res 1994; 85(8): 840–6 Zafon C, Obiols G, Castellví J, et al. nm23-H1 immunoreactivity as a prognostic factor in differentiated thyroid carcinoma. J Clin Endocrinol Metab 2001; 86(8): 3975–80 Sirotkovic-Skerlev M, Krizanac S, Kapitanovic S, et al. Expression of c-myc, erbB-2, p53 and nm23-H1 gene product in benign and malignant breast lesions: coexpression and correlation with clinicopathologic parameters. Exp Mol Pathol 2005; 79(1): 42–50 Shiau AK, Barstad D, Loria PM, et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998; 95(7): 927–37 Driscoll MD, Sathya G, Muyan M, et al. Sequence requirements for estrogen receptor binding to estrogen response elements. J Biol Chem 1998; 273(45): 29321–30 Kato S, Tora L, Yamauchi J, et al. A far upstream estrogen response element of the ovalbumin gene contains several half-palindromic 5′-TGACC-3′ motifs acting synergistically. Cell 1992; 68(4): 731–42 Näär AM, Boutin JM, Lipkin SM, et al. The orientation and spacing of core DNA-binding motifs dictate selective transcriptional responses to three nuclear receptors. Cell 1991; 65(7): 1267–79 Curtis CD, Likhite VS, McLeod IX, et al. Interaction of the tumor metastasis suppressor nonmetastatic protein 23 homologue H1 and estrogen receptor A alters estrogen-responsive gene expression. Cancer Res 2007; 67(21): 10600–7 Ouatas T, Salerno M, Palmieri D, et al. Basic and translational advances in cancer metastasis: Nm23. J Bioenerg Biomembr 2003; 35: 73–9 Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999; 17: 976–83 Beenken SW, Grizzle WE, Crowe DR, et al. Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and p53. Ann Surg 2001; 233(5): 630–8 Tsutsui S, Ohno S, Murakami S, et al. Prognostic significance of the coexpression of p53 protein and c-erbB2 in breast cancer. Am J Surg 2003; 185: 165–7 Patani N, Mokbel K. Herceptin and breast cancer: an overview for surgeons. Surg Oncol 2010; 19(1): e11–21 Steeg PS, Horak CE, Miller KD. Clinical-translational approaches to the Nm23-H1 metastasis suppressor. Clin Cancer Res 2008; 14(16): 5006–12 Marshall JC, Lee JH, Steeg PS. Clinical-translational strategies for the elevation of Nm23-H1 metastasis suppressor gene expression. Mol Cell Biochem 2009; 329(1–2): 115–20 Steeg PS, Ouatas T, Halverson D, et al. Metastasis suppressor genes: basic biology and potential clinical use. Clin Breast Cancer 2003; 4: 51–62